Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ERN1 | O75460 | 4/20 | 0.43 |
| ▸ | ALDH5A1 | P51649 | 2/20 | 0.42 |
| ▸ | ABAT | P80404 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753265 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ERN1ALDH5A1ABATLCK | |
| SCHEMBL4575600 | 0.82 | ALDH5A1 (0.52) | ALDH1A1ALDH5A1ABATLCKKDM4E | |
| SCHEMBL37131 | 0.82 | LCK (0.58) | ALDH1A1ALDH5A1ABATLCKKDM4E | |
| SCHEMBL9261197 | 0.82 | LCK (0.58) | ALDH1A1ALDH5A1ABATLCKKDM4E | |
| SCHEMBL646947 | 0.82 | ALDH1A1 (0.56) | ALDH1A1ERN1ALDH5A1ABATKDM4E | |
| SCHEMBL708554 | 0.82 | ALDH1A1 (0.56) | ALDH1A1ERN1ALDH5A1ABATKDM4E | |
| Potassium SCHEMBL31540630 | 0.79 | LCK (0.55) | ALDH1A1ALDH5A1ABATLCKKDM4E | |
| Phloroglucinol SCHEMBL28580013 | 0.76 | ALDH5A1 (0.52) | ALDH1A1ALDH5A1ABATLCKKDM4E | |
| SCHEMBL16955787 | 0.76 | LCK (0.40) | ALDH1A1LCKKDM4EPTGS2RAB9A | |
| SCHEMBL25180638 | 0.73 | KDM4E (0.53) | ALDH1A1LCKKDM4EPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0423010-B1 | METHOD FOR THE PRODUCTION OF ALKOXYBENZALDEHYDES | RHONE-POULENC CHIMIE (FR) | 1993-09-29 | — | — | EP | claimed |
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260078094-A1 | ANTI-VIRAL COMPOUNDS | INFEX THERAPEUTICS LTD (GB) | 2026-03-19 | — | — | US | disclosed |
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4587425-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| CN-119866328-A | Antiviral compounds | 英菲克斯治疗有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119855814-A | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4532491-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008141462-A9 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008141462-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008058387-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-05-22 | — | — | WO | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2005037756-A2 | NOVEL METHODS FOR THE PREPARATION OF 4-[4-(4-METHOXYMETHOXY-4'-METHYL-BIPHENYL-2-YL)-BUT-3-ENE-(E)-1-YNYL]-BENZOIC ACID | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042745-A1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | ALDH1A1 1803/4885ERN1 2321/4885ALDH5A1 1839/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | ALDH1A1 1720/4885ERN1 2687/4885ALDH5A1 949/4885 |
| US-20260078094-A1 | ANTI-VIRAL COMPOUNDS | CBR1, CBR3, CPN1 | ALDH1A1 3141/4885ERN1 164/4885ALDH5A1 4031/4885 |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | ALDH1A1 1720/4885ERN1 2687/4885ALDH5A1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.